• Arteris, Inc. recently expanded its partnership with Arm to integrate its Cycuity Radix hardware security assurance technology across more next‑generation CPU programs, while its FlexNoC interconnect has been deployed in Speedata’s data center analytics processing unit for high-performance workloads.
• Together, these moves highlight Arteris’ growing role in securing advanced processor designs and powering specialized analytics hardware that targets demanding AI and data workloads.
• Next, we’ll examine how deeper Arm integration of Cycuity Radix could influence Arteris’ investment narrative around AI-era semiconductor IP demand.

AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Arteris Investment Narrative Recap

To own Arteris, you need to believe its network‑on‑chip and security IP remain central to increasingly complex, AI‑focused chips, and that growing license and royalty streams can eventually outweigh ongoing losses and high R&D spend. The expanded Arm security partnership and Speedata APU win both speak directly to the AI and chiplet catalysts, but they do not, by themselves, resolve near term pressure around profitability and customer concentration risk.

Among recent announcements, the Arm agreement stands out here, since wider integration of Cycuity Radix into Arm CPU programs ties Arteris more tightly to a leading compute ecosystem that already underpins many AI and data center designs. That deeper technical embed could support the thesis that AI‑era chip complexity favors outsourced IP, yet it also brings the customer concentration risk into sharper focus if Arm or other large accounts ever change direction.

However, investors should also weigh how Arteris’s reliance on a handful of major customers could become a problem if any one of them decides to...

Arteris' narrative projects $151.4 million revenue and $18.3 million earnings by 2029.

Uncover how Arteris' forecasts yield a $37.75 fair value, a 13% upside to its current price.

Exploring Other Perspectives

While recent Arm and Speedata wins may appear to validate Arteris’s AI thesis, the most cautious analysts still assume about US$149.4 million revenue and only US$18.1 million earnings by 2029, reminding you that opinions on margin pressure and client dependence can differ widely and that this new information could shift those expectations.

Explore 5 other fair value estimates on Arteris - why the stock might be worth less than half the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Arteris research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Arteris research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Arteris' overall financial health at a glance.

Curious About Other Options?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Capitalize on the AI infrastructure supercycle with our selection of the 54 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Find 47 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.